Goldman Sachs Group Inc. upgraded Galapagos NV (ADR) (NASDAQ:GLPG) to Buy in a report released today.
- Updated: October 19, 2016
Goldman Sachs Group Inc. has upgraded Galapagos NV (ADR) (NASDAQ:GLPG) to Buy in a report released on Tuesday October 18, 2016.
Having a price of $65.82, Galapagos NV (ADR) (NASDAQ:GLPG) traded -1.47% lower on the day. With the last close up 21.01% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $62.06 and a two hundred day average of $54.39. Volume of trade was down over the average, with 87,746 shares of GLPG changing hands under the typical 91,894
With a total market value of $0, Galapagos NV (ADR) has with a one year low of $37.03 and a one year high of $73.37 .
A total of 1 equity analyst has released a ratings update on GLPG. zero equity analysts rating the company a strong buy, two equity analysts rating the company a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $92.78.
General Information About Galapagos NV (ADR) (NASDAQ:GLPG)
Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.